Congenital hypomyelinating neuropathy due to a novel MPZ mutation

• Published in: Journal of the peripheral nervous system 2011-12, Vol.16 (4), p.347-352
• Main Authors: Sevilla, Teresa, Lupo, Vincenzo, Sivera, Rafael, Marco-Marín, Clara, Martínez-Rubio, Dolores, Rivas, Eloy, Hernández, Arturo, Palau, Francesc, Espinós, Carmen
• Format: Article
• Language: English
• Subjects: Allium cepa; Axons; Biopsy; Bulbs; Cell adhesion; Cell membranes; Cell surface; Charcot-Marie-Tooth; Charcot-Marie-Tooth Disease - genetics; Child, Preschool; congenital hypomyelinating neuropathy; Cranial nerves; Cytosol; Demyelination; DNA Mutational Analysis; Déjérine-Sottas syndrome; Humans; Male; Missense mutation; Molecular modelling; MPZ gene; Mutation, Missense; Myelin P0 Protein - genetics; Neonates; nerve biopsy; Nerve conduction; Neuropathy; Phenylalanine; Protein folding; Serine; sural nerve
• ISSN: 1085-9489; 1529-8027
• DOI: 10.1111/j.1529-8027.2011.00369.x

Congenital hypomyelinating neuropathy (CHN) is a severe inherited neuropathy with neonatal or early infancy onset, reduced nerve conduction velocity, and pathological evidence of hypomyelination. We describe a case of CHN that presented with neonatal hypotonia and a progressive downhill clinical course, developing cranial nerve dysfunction, and respiratory failure. The nerve conduction velocities were severely slowed and sural nerve biopsy revealed non‐myelinated and poorly myelinated axons, with no typical onion bulbs. The mutational screening showed that our proband harbored a novel missense mutation, p.S121F, in the MPZ gene. In silico analyses and molecular modeling predicted that the replacement of a serine by a phenylalanine is a non‐tolerated change and may affect the folding and the stability of the protein. Subcellular location studies were performed and revealed that the mutant protein loses its correct location on the cell membrane surface and is mainly expressed in the cytosol, reducing its adhesive properties. This case illustrates the clinical heterogeneity that exists in neuropathies associated with MPZ mutations and highlights that in patients with mild hypotonia in the first months that develop a very severe demyelinating neuropathy, the MPZ gene must be taken into account.